『Hospital Medicine Unplugged』のカバーアート

Hospital Medicine Unplugged

Hospital Medicine Unplugged

著者： Roger Musa MD and Eric Bachrach MD
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

Hospital Medicine Unplugged delivers evidence-based updates for hospitalists—no fluff, just the facts. Each 30-minute episode breaks down the latest guidelines, clinical pearls, and practical strategies for inpatient care. From antibiotics to risk stratification, radiology to discharge planning, you’ll get streamlined insights you can apply on the wards today. Perfect for busy physicians who want clarity, accuracy, and relevance in hospital medicine.

Roger Musa MD and Eric Bachrach MD 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Thalassemias: Genetics, Pathophysiology, and Clinical Manifestations in the Hospitalized Patient

    Thalassemias: Genetics, Pathophysiology, and Clinical Manifestations in the Hospitalized Patient
    2026/04/06

    In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide.

    We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact.

    Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis.

    We then dive into the genetic architecture. α-globin genes (HBA1, HBA2) sit on chromosome 16 with four total copies, while the β-globin gene (HBB) lies on chromosome 11 with two total copies.

    • α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2. • β-thalassemia typically results from point mutations affecting transcription, RNA splicing, or translation.

    Mutations are classified as: • β⁰ mutations: no β-globin production • β⁺ mutations: reduced β-globin synthesis

    Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression.

    Next, we map the clinical classification.

    Alpha thalassemia spectrum: • Silent carrier: one gene affected, usually asymptomatic • α-thalassemia trait: two genes affected, mild microcytic anemia • Hemoglobin H disease: three genes affected → moderate-severe hemolytic anemia with β₄ tetramers • Hb Bart’s hydrops fetalis: four genes deleted → incompatible with life

    Beta thalassemia spectrum: • β-thalassemia trait: mild microcytic anemia with elevated HbA₂ (>3.5%) • β-thalassemia intermedia: moderate anemia with variable transfusion needs • β-thalassemia major (Cooley anemia): severe disease presenting in infancy requiring lifelong transfusions

    Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations.

    Then we unpack the pathophysiology driving complications.

    Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to: • Ineffective erythropoiesis with massive marrow expansion • Hemolysis from fragile red cells • Extramedullary hematopoiesis in liver and spleen

    Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities.

    Iron overload develops through two major pathways: • Transfusion iron loading (each unit adds ~200–250 mg of iron) • Increased intestinal absorption from suppressed hepcidin due to ineffective erythropoiesis

    The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk.

    We close with the clinical spectrum.

    • Trait: usually asymptomatic with incidental microcytosis • Intermedia: moderate anemia (Hb ~7–10 g/dL), skeletal changes, gallstones, pulmonary hypertension, extramedullary masses • Major: early infancy presentation with severe anemia, failure to thrive, hepatosplenomegaly, and the classic “chipmunk facies” from marrow expansion

    Bottom line: thalassemia is a disorder of globin chain imbalance leading to ineffective erythropoiesis, hemolysis, marrow expansion, and iron overload. Understanding the genetics, modifiers, and pathophysiology is essential to predicting severity, guiding transfusion strategies, and preventing the devastating end-organ complications of chronic iron toxicity.
    続きを読む 一部表示
    36 分
  • Clinical Guide to Axial Spondyloarthritis and Ankylosing Spondylitis

    Clinical Guide to Axial Spondyloarthritis and Ankylosing Spondylitis
    2026/04/03
    In this episode of Hospital Medicine Unplugged, we sprint through ankylosing spondylitis and axial spondyloarthritis—recognize inflammatory back pain early, understand the disease spectrum from non-radiographic to radiographic disease, and treat aggressively to prevent structural damage and disability. We begin with the modern concept of axial spondyloarthritis (axSpA), which represents a disease spectrum rather than a single condition. At one end is non-radiographic axial spondyloarthritis (nr-axSpA)—patients with typical symptoms but without definitive radiographic sacroiliitis. At the other end is radiographic axial spondyloarthritis (r-axSpA), historically known as ankylosing spondylitis, where structural changes in the sacroiliac joints are visible on X-ray. Globally, axial spondyloarthritis affects roughly 0.3% to 1.4% of the population, with about 1% prevalence in the United States. Disease onset typically occurs early in life—more than 80% of patients develop symptoms before age 30. Radiographic disease is more common in men, while non-radiographic disease occurs equally in men and women. A major challenge in this condition is diagnostic delay, which averages nearly seven years from symptom onset. This delay contributes to progressive inflammation, structural damage, and functional impairment before effective therapy is started. The pathogenesis of axial spondyloarthritis involves a combination of genetic susceptibility, immune dysregulation, and environmental triggers. The strongest genetic risk factor is HLA-B27, present in 80–90% of patients with ankylosing spondylitis. Several mechanisms have been proposed to explain how HLA-B27 contributes to disease: • Presentation of arthritogenic peptides to CD8+ T cells • Formation of HLA-B27 dimers, which activate innate immune receptors • Misfolding of HLA-B27 proteins, triggering an unfolded protein response and increased cytokine signaling At the center of the inflammatory cascade lies the IL-23 / IL-17 axis, which drives activation of Th17 cells and production of pro-inflammatory cytokines including IL-17 and TNF-α. Mechanical stress at the entheses—the sites where ligaments and tendons attach to bone—triggers inflammation, making enthesitis the hallmark pathological process. Chronic inflammation eventually stimulates pathologic new bone formation, producing syndesmophytes and spinal ankylosis. Clinically, the hallmark symptom is inflammatory back pain, present in more than 80% of patients. Key features include: • Onset before age 45 years • Gradual onset • Morning stiffness lasting more than 30 minutes • Improvement with exercise • No improvement with rest Extra-articular manifestations are common and often provide diagnostic clues. The most frequent is acute anterior uveitis, occurring in 25–30% of patients. Episodes typically present with sudden eye pain, redness, photophobia, and blurred vision. Other associated conditions include: • Inflammatory bowel disease (5–10%) • Psoriasis (about 10%) • Cardiovascular involvement, including aortic regurgitation and conduction abnormalities • Pulmonary restriction due to chest wall rigidity Because early disease may not show radiographic damage, classification relies on modern criteria. The Modified New York Criteria require definite radiographic sacroiliitis and therefore identify only advanced disease. In contrast, the ASAS classification criteria for axial spondyloarthritis allow earlier diagnosis. These criteria apply to patients with chronic back pain lasting ≥3 months with onset before age 45 and include two diagnostic pathways: • Imaging arm: sacroiliitis on MRI or radiograph plus ≥1 SpA feature • Clinical arm: HLA-B27 positivity plus ≥2 SpA features These criteria have approximately 83% sensitivity and 84% specificity, enabling detection of earlier disease stages. Monitoring disease activity is critical to guide treatment decisions. The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred measure because it incorporates both patient-reported symptoms and inflammatory markers such as CRP. ASDAS categories include: • Inactive disease: <1.3 • Low activity: 1.3–2.1 • High activity: 2.1–3.5 • Very high activity: >3.5 Management begins with non-pharmacologic therapy, which remains foundational for all patients. This includes structured exercise programs, physical therapy, posture training, and smoking cessation, as smoking is associated with worse radiographic progression and poorer treatment response. First-line pharmacologic therapy is NSAIDs, which reduce pain and inflammation. Continuous therapy may be more effective than intermittent use, although fewer than one quarter of patients achieve complete symptom control with NSAIDs alone. For patients with persistent disease activity, biologic therapy is the next step. TNF inhibitors were the first biologics proven effective, producing ASAS20 response rates of roughly 60% ...
    続きを読む 一部表示
    22 分
  • Prosthetic Heart Valve Selection and Clinical Management Guide for the Hospitalist

    Prosthetic Heart Valve Selection and Clinical Management Guide for the Hospitalist
    2026/04/01
    In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement. We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist. Anticoagulation targets depend on valve position and risk factors. • Mechanical aortic valve: target INR 2.5 • Mechanical mitral valve or high-risk aortic valve: target INR 3.0 In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk. Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing. Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation. Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly: • Aortic valve replacement: survival benefit up to about age 55 • Mitral valve replacement: survival benefit up to about age 70 Current ACC/AHA guidelines generally recommend: • Mechanical valves: younger patients (<50 years for aortic position, <65 years for mitral) • Bioprosthetic valves: older patients or those with contraindications to long-term anticoagulation The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups. Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation. Guidelines now recommend: • TAVR as a Class I option for patients who are inoperable or high surgical risk • Either TAVR or surgical replacement for patients aged 65–80 years, depending on anatomy and patient factors Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events. For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited. Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations. Another major complication is prosthetic valve thrombosis, particularly with mechanical valves. Management depends on clinical severity and thrombus size. Options include urgent surgery or low-dose, slow-infusion fibrinolysis, with modern thrombolytic protocols achieving over 90% success rates and low complication rates. A subtler but clinically important issue is prosthesis–patient mismatch (PPM). This occurs when the effective orifice area of the prosthetic valve is too small relative to the patient’s body surface area, creating persistent obstruction despite valve replacement. Severe PPM is defined as indexed effective orifice area <0.65 cm²/m² and is associated with higher mortality, reduced left ventricular mass regression, and worse heart failure outcomes. Certain populations require special consideration. Pregnancy with mechanical valves carries substantial maternal and fetal risk due to the competing challenges of anticoagulation and thrombosis prevention. Warfarin provides the most reliable valve protection but carries risk of embryopathy ...
    続きを読む 一部表示
    35 分
まだレビューはありません